Access Pharmaceuticl (ACCP) 0.4528 $ACCP
Access Pharmaceuticals MuGard Selected For Cover Article In The Print Edition Of The Journal Cancer
PR Newswire - Thu May 01, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional post-approval trial of MuGard® that was recently published in Cancer, has been selected as a cover article in the premier publication. Cancer, the journal of the American Cancer Society is one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck. In the trial, MuGard was shown to be superior to the sham control saline-bicarbonate rinse in mitigating oral mucositis symptoms and delaying oral mucositis progression.
Positive Results Of MuGard Study In Erosive Oral Lichen Planus Presented At International Oral Medicine Meeting
PR Newswire - Tue Apr 15, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that positive results from a study conducted at Nova Southeastern University were presented recently at the Frontiers in Oral Medicine 2014 conference, hosted by the American Academy of Oral Medicine, in Orlando, Florida. The poster, entitled "Effectiveness of a Polymer-Based Muco-Adhesive (MuGard®) in the Healing of Oral Ulcers in Erosive Lichen Planus: A Pilot Study" reflected results of a randomized, doubled-blinded study (1:1 randomization into MuGard® or bicarbonate rinse arm) of 20 patients with biopsy proven oral lichen planus. Patients in the MuGard® arm had statistically significant improvement in ulcerations and pain, and the changes in pain were closely related to the health of the ulcers. There was no statistically significant change in erythema.
Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox
PR Newswire - Tue Apr 08, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard(TM), for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries, in numerous formulations, for the treatment of a variety of conditions including recurrent aphthous ulceration (RAU), bronchial asthma and allergic rhinitis. Amlexanox is known to inhibit formation and release of histamine, TNF-alpha and leukotriene from mast cells, basophils and neutrophils, and has strong anti-inflammatory effects in mucosal tissue with few adverse effects. By formulating amlexanox in its proprietary mucoadhesive polymer hydrogel delivery system, Access has a patented and protectable formulation of this interesting pharmaceutical active.
Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology
PR Newswire - Tue Apr 01, 7:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and includes the ability to act as a delivery system for a variety of active agents, including drugs.
Access Pharmaceuticals Cobraxane(TM) Offers Enhanced Tumor Growth Inhibition In Tumor Models
PR Newswire - Wed Mar 26, 7:14AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane(TM), its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane® in a standard mouse tumor model. At a dose of Cobraxane(TM) which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane(TM) demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Cobraxane(TM), injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane(TM). Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane(TM).
Access Pharmaceuticals Advances Development of ProctiGard(TM) for Radiation Proctitis
PR Newswire - Fri Mar 21, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP"
is a significant unmet medical need, with no well-established standard of care. It is estimated that there are in excess of 250,000 new cases of prostate, cervical, rectal, testicular, bladder and endometrial cancer diagnosed each year. Approximately 50% of these patients require radiation therapy, and roughly 75% of patients undergoing pelvic irradiation experience radiation proctitis. Access is actively seeking marketing partners globally for ProctiGard(TM).
Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
PR Newswire - Tue Mar 11, 7:52AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) today announced that it had entered into an exclusive license agreement with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard commercialization in South Korea. Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients in the US alone developing the condition each year.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal
PR Newswire - Tue Feb 18, 7:30AM CST
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced the online early publication of the final results of its post-approval marketing study of MuGard® in Cancer, the journal of the American Cancer Society and one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. The publication discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Market Research: Male Infertility - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kpkhxw/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H2 2013" report to their offering. 'Male Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Infertility. Scope - A snapshot of the global therapeutic scenario for Male Infertility. - A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Male Infertility. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned ASKA Pharmaceutical Co., Ltd Zydus Cadila Healthcare Limited Access Pharmaceuticals, Inc. Intas Pharmaceuticals Ltd. Pantarhei Bioscience BV Cordex Pharma, Inc. Trophogen, Inc. For more information visit http://www.researchandmarkets.com/research/kp...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013
M2 - Wed Nov 20, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/rqj9pj/bile_duct_cancer) has announced the addition of the "Global Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013" report to their offering. 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . Scope - A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma) . - A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) . - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Bile Duct Cancer (Cholangiocarcinoma) Overview Therapeutics Development Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development Drug Profiles - vandetanib - AP-5346 - Im-0 - triphendiol - SPI-1620 - elpamotide - exatecan mesylate - WT-1 Peptide Vaccine [gemcitabine] - gemcitabine - curcumin [gemcitabine hydrochloride] - NUC-1031 - JP-1584 - CAP-7.1 Featured News & Press Releases Appendix Companies Mentioned - Access Pharmaceuticals - AstraZeneca - CellAct Pharma - Daiichi Sankyo Company - Marshall Edwards - Mebiopharm - NuCana BioMed - Novartis - OncoTherapy Science - Provecs Medical - PCI Biotech - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/rq...uct_cancer
Ovarian Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Ovarian Cancer
M2 - Wed Nov 06, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/2rp465/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Ovarian Cancer. - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Novartis AG - Samyang Corporation - Aphios Corporation - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - AntiCancer, Inc. - Merck KGaA - Access Pharmaceuticals, Inc. - Advaxis, Inc. - Innocell Corporation - PharmaGap Inc. - TRION Pharma GmbH - Advantagene, Inc. - BioNumerik Pharmaceuticals, Inc. - Alethia Biotherapeutics Inc. - OnKor Pharmaceuticals, Inc. - Coronado Biosciences, Inc. - Cerulean Pharma, Inc. - Heat Biologics, Inc. - PepTx, Inc. - Mebiopharm Co., Ltd. - DEKK-TEC, Inc. - ISA Pharmaceuticals B.V. - TAU Therapeutics, LLC - Gradalis Inc. For more information visit http://www.researchandmarkets.com/research/2r...ian_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Awarded Second European Patent for MuGard
PR Newswire Europe - Thu Sep 12, 7:31AM CDT
-- Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets
Women Infertility - Pipeline Review, H2 2013 Report Features Players such as Merck KGaA, EndoCeutics, Inc. and Quatrx Pharmaceutical Company
M2 - Thu Aug 08, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksmjh2/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Women Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women Infertility. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Women Infertility. - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Women Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ASKA Pharmaceutical Co., Ltd - Access Pharmaceuticals, Inc. - Addex Pharmaceuticals - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Camurus AB - Crinetics Pharmaceuticals, Inc. - DONGKOOK Pharmaceutical Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Euroscreen S.A. - Evotec Aktiengesellschaft - Ferring Pharmaceuticals, Inc. - Glycotope GmbH - IBSA Farmaceutici Italia Srl - Intas Pharmaceuticals Ltd. - Isifer AB - JCR Pharmaceuticals Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Neurocrine Biosciences, Inc. - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - Peptron, Inc. - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Repros Therapeutics Inc. - Takeda Pharmaceutical Company Limited - Techpool Bio-Pharma Co., LTD. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - ValiRx Plc - Watson Pharmaceuticals, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/ks...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lz5x26/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma). - A review of the Bile Duct Cancer (Cholangiocarcinoma)products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bile Duct Cancer (Cholangiocarcinoma)pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Overview Bile Duct Cancer (Cholangiocarcinoma) Overview Therapeutics Development An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Access Pharmaceuticals - AstraZeneca - Karo Bio - Marshall Edwards - Mebiopharm Co - Novartis - OncoTherapy Science - Provecs Medical GmbH - Simcere Pharmaceutical Group For more information visit http://www.researchandmarkets.com/research/lz...uct_cancer
Access Pharmaceuticals To Host Investor Call On Wednesday, July 31, 2013
PR Newswire - Fri Jul 26, 10:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on recent company developments. The investor conference call is scheduled to be held on Wednesday, July 31, 2013 at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Access Pharmaceuticals Announces Positive Top-Line Data From MuGard(TM) Phase IV Clinical Trial In Oral Mucositis Patients Presented At MASCC/ISOO 2013 Symposium
PR Newswire - Thu Jun 27, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented top-line results today from a phase IV clinical trial evaluating MuGard(TM) Mucoadhesive Oral Wound Rinse at the MASCC/ISOO International Symposium on Supportive Care in Cancer in Berlin, Germany. The prospective, randomized, multi-center, double-blind, placebo-controlled study evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
PR Newswire - Mon Jun 10, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) related to the commercialization of MuGard(TM) in the US and its territories. Under the terms of the license agreement, Access will receive an upfront licensing fee of $3.3 million and a tiered, double digit royalty on net sales of MuGard in the licensed territories. AMAG will also purchase existing MuGard inventory from Access. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients developing the condition each year.
Male Infertility - Pipeline Review, H1 2013 Contains a Snapshot of the Global Therapeutic Scenario for Male Infertility
M2 - Tue Jun 04, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dh6c7p/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Male Infertility - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Infertility. Male Infertility - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: ASKA Pharmaceutical Co., Ltd Zydus Cadila Healthcare Limited Access Pharmaceuticals, Inc. Pantarhei Bioscience BV Cordex Pharma, Inc. Trophogen, Inc. For more information visit http://www.researchandmarkets.com/research/dh...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals MuGard Selected For Cover Article In The Print Edition Of The Journal Cancer
PR Newswire - Thu May 01, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that the data from its multi-institutional post-approval trial of MuGard® that was recently published in Cancer, has been selected as a cover article in the premier publication. Cancer, the journal of the American Cancer Society is one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck. In the trial, MuGard was shown to be superior to the sham control saline-bicarbonate rinse in mitigating oral mucositis symptoms and delaying oral mucositis progression.
Positive Results Of MuGard Study In Erosive Oral Lichen Planus Presented At International Oral Medicine Meeting
PR Newswire - Tue Apr 15, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that positive results from a study conducted at Nova Southeastern University were presented recently at the Frontiers in Oral Medicine 2014 conference, hosted by the American Academy of Oral Medicine, in Orlando, Florida. The poster, entitled "Effectiveness of a Polymer-Based Muco-Adhesive (MuGard®) in the Healing of Oral Ulcers in Erosive Lichen Planus: A Pilot Study" reflected results of a randomized, doubled-blinded study (1:1 randomization into MuGard® or bicarbonate rinse arm) of 20 patients with biopsy proven oral lichen planus. Patients in the MuGard® arm had statistically significant improvement in ulcerations and pain, and the changes in pain were closely related to the health of the ulcers. There was no statistically significant change in erythema.
Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox
PR Newswire - Tue Apr 08, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard(TM), for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries, in numerous formulations, for the treatment of a variety of conditions including recurrent aphthous ulceration (RAU), bronchial asthma and allergic rhinitis. Amlexanox is known to inhibit formation and release of histamine, TNF-alpha and leukotriene from mast cells, basophils and neutrophils, and has strong anti-inflammatory effects in mucosal tissue with few adverse effects. By formulating amlexanox in its proprietary mucoadhesive polymer hydrogel delivery system, Access has a patented and protectable formulation of this interesting pharmaceutical active.
Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology
PR Newswire - Tue Apr 01, 7:16AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and includes the ability to act as a delivery system for a variety of active agents, including drugs.
Access Pharmaceuticals Cobraxane(TM) Offers Enhanced Tumor Growth Inhibition In Tumor Models
PR Newswire - Wed Mar 26, 7:14AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of Cobraxane(TM), its proprietary nanoparticle formulation of commercially available protein-bound paclitaxel, with Abraxane® in a standard mouse tumor model. At a dose of Cobraxane(TM) which was half that of the maximum tolerated dose (MTD) of the standard paclitaxel particles, Cobraxane(TM) demonstrated slightly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Cobraxane(TM), injected at the same dose as the MTD dose of standard paclitaxel particles, provided significantly better tumor growth inhibition than the MTD dose of standard paclitaxel particles. Tumor shrinkage was observed at the higher dose of Cobraxane(TM). Access believes the preclinical data observed is a strong indicator of potential clinical and commercial value of Cobraxane(TM).
Access Pharmaceuticals Advances Development of ProctiGard(TM) for Radiation Proctitis
PR Newswire - Fri Mar 21, 7:30AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has advanced development of a new proprietary product, called ProctiGard(TM), for the treatment of radiation proctitis. Radiation proctitis ("RP"
is a significant unmet medical need, with no well-established standard of care. It is estimated that there are in excess of 250,000 new cases of prostate, cervical, rectal, testicular, bladder and endometrial cancer diagnosed each year. Approximately 50% of these patients require radiation therapy, and roughly 75% of patients undergoing pelvic irradiation experience radiation proctitis. Access is actively seeking marketing partners globally for ProctiGard(TM). Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
PR Newswire - Tue Mar 11, 7:52AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) today announced that it had entered into an exclusive license agreement with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard commercialization in South Korea. Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients in the US alone developing the condition each year.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal
PR Newswire - Tue Feb 18, 7:30AM CST
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced the online early publication of the final results of its post-approval marketing study of MuGard® in Cancer, the journal of the American Cancer Society and one of the oldest peer-reviewed journals in oncology. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. The publication discusses data on Access' post-marketing clinical trial that evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Market Research: Male Infertility - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kpkhxw/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H2 2013" report to their offering. 'Male Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Infertility. Scope - A snapshot of the global therapeutic scenario for Male Infertility. - A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Male Infertility. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned ASKA Pharmaceutical Co., Ltd Zydus Cadila Healthcare Limited Access Pharmaceuticals, Inc. Intas Pharmaceuticals Ltd. Pantarhei Bioscience BV Cordex Pharma, Inc. Trophogen, Inc. For more information visit http://www.researchandmarkets.com/research/kp...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013
M2 - Wed Nov 20, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/rqj9pj/bile_duct_cancer) has announced the addition of the "Global Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013" report to their offering. 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . Scope - A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma) . - A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) . - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Bile Duct Cancer (Cholangiocarcinoma) Overview Therapeutics Development Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development Drug Profiles - vandetanib - AP-5346 - Im-0 - triphendiol - SPI-1620 - elpamotide - exatecan mesylate - WT-1 Peptide Vaccine [gemcitabine] - gemcitabine - curcumin [gemcitabine hydrochloride] - NUC-1031 - JP-1584 - CAP-7.1 Featured News & Press Releases Appendix Companies Mentioned - Access Pharmaceuticals - AstraZeneca - CellAct Pharma - Daiichi Sankyo Company - Marshall Edwards - Mebiopharm - NuCana BioMed - Novartis - OncoTherapy Science - Provecs Medical - PCI Biotech - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/rq...uct_cancer
Ovarian Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Ovarian Cancer
M2 - Wed Nov 06, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/2rp465/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Ovarian Cancer. - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Novartis AG - Samyang Corporation - Aphios Corporation - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - AntiCancer, Inc. - Merck KGaA - Access Pharmaceuticals, Inc. - Advaxis, Inc. - Innocell Corporation - PharmaGap Inc. - TRION Pharma GmbH - Advantagene, Inc. - BioNumerik Pharmaceuticals, Inc. - Alethia Biotherapeutics Inc. - OnKor Pharmaceuticals, Inc. - Coronado Biosciences, Inc. - Cerulean Pharma, Inc. - Heat Biologics, Inc. - PepTx, Inc. - Mebiopharm Co., Ltd. - DEKK-TEC, Inc. - ISA Pharmaceuticals B.V. - TAU Therapeutics, LLC - Gradalis Inc. For more information visit http://www.researchandmarkets.com/research/2r...ian_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Access Pharmaceuticals Awarded Second European Patent for MuGard
PR Newswire Europe - Thu Sep 12, 7:31AM CDT
-- Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets
Women Infertility - Pipeline Review, H2 2013 Report Features Players such as Merck KGaA, EndoCeutics, Inc. and Quatrx Pharmaceutical Company
M2 - Thu Aug 08, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksmjh2/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Women Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women Infertility. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Women Infertility. - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Women Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ASKA Pharmaceutical Co., Ltd - Access Pharmaceuticals, Inc. - Addex Pharmaceuticals - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Camurus AB - Crinetics Pharmaceuticals, Inc. - DONGKOOK Pharmaceutical Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Euroscreen S.A. - Evotec Aktiengesellschaft - Ferring Pharmaceuticals, Inc. - Glycotope GmbH - IBSA Farmaceutici Italia Srl - Intas Pharmaceuticals Ltd. - Isifer AB - JCR Pharmaceuticals Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Neurocrine Biosciences, Inc. - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - Peptron, Inc. - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Repros Therapeutics Inc. - Takeda Pharmaceutical Company Limited - Techpool Bio-Pharma Co., LTD. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - ValiRx Plc - Watson Pharmaceuticals, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/ks...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lz5x26/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma). - A review of the Bile Duct Cancer (Cholangiocarcinoma)products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bile Duct Cancer (Cholangiocarcinoma)pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Overview Bile Duct Cancer (Cholangiocarcinoma) Overview Therapeutics Development An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Access Pharmaceuticals - AstraZeneca - Karo Bio - Marshall Edwards - Mebiopharm Co - Novartis - OncoTherapy Science - Provecs Medical GmbH - Simcere Pharmaceutical Group For more information visit http://www.researchandmarkets.com/research/lz...uct_cancer
Access Pharmaceuticals To Host Investor Call On Wednesday, July 31, 2013
PR Newswire - Fri Jul 26, 10:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on recent company developments. The investor conference call is scheduled to be held on Wednesday, July 31, 2013 at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Access Pharmaceuticals Announces Positive Top-Line Data From MuGard(TM) Phase IV Clinical Trial In Oral Mucositis Patients Presented At MASCC/ISOO 2013 Symposium
PR Newswire - Thu Jun 27, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented top-line results today from a phase IV clinical trial evaluating MuGard(TM) Mucoadhesive Oral Wound Rinse at the MASCC/ISOO International Symposium on Supportive Care in Cancer in Berlin, Germany. The prospective, randomized, multi-center, double-blind, placebo-controlled study evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.
Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
PR Newswire - Mon Jun 10, 7:00AM CDT
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) related to the commercialization of MuGard(TM) in the US and its territories. Under the terms of the license agreement, Access will receive an upfront licensing fee of $3.3 million and a tiered, double digit royalty on net sales of MuGard in the licensed territories. AMAG will also purchase existing MuGard inventory from Access. MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients developing the condition each year.
Male Infertility - Pipeline Review, H1 2013 Contains a Snapshot of the Global Therapeutic Scenario for Male Infertility
M2 - Tue Jun 04, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dh6c7p/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Male Infertility - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Infertility. Male Infertility - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: ASKA Pharmaceutical Co., Ltd Zydus Cadila Healthcare Limited Access Pharmaceuticals, Inc. Pantarhei Bioscience BV Cordex Pharma, Inc. Trophogen, Inc. For more information visit http://www.researchandmarkets.com/research/dh...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
